Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
28 March, 2025
TROG Awards Recognise Research Excellence
Latest news: 28 March 2025. TROG Members who have
27 March, 2025
TROG 2025 ASM advances inclusivity and innovation
Latest news: 27 March 2025 With a theme of
